Stocktoria
ZEVRA THERAPEUTICS, INC. ZVRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-04-16
ZEVRA THERAPEUTICS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -59.1% | -368.5% | -180.6% | -418.9% | 27.0% |
| Net margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% |
| FCF margin | -2.3% | -295.0% | -123.2% | -185.1% | 36.1% |
| Return on assets | 29.2% | -59.2% | -26.7% | -23.2% | -6.4% |
| Return on equity | 53.8% | -266.0% | -74.4% | -35.6% | -8.4% |
| Debt / equity | 0.40× | 1.50× | 0.08× | — | — |
| Current ratio | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 |
| Revenue growth | 350.9% | -14.0% | 170.3% | -64.5% | 115.6% |
Source: SEC EDGAR filings · CIK 0001434647 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.